Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.

@article{Soria2015AfatinibVE,
  title={Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.},
  author={Jean – Charles Soria and E Felip and M. T. Carrillo Cobo and Shun Lu and Konstantinos Syrigos and Ki Hyeong Lee and Erdem G{\"o}ker and Vassilis Georgoulias and Wei Li and Dolores Isla and Salih Zeki Guclu and Alessandro Morabito and Young Joo Min and Andrea Ardizzoni and Shirish M. Gadgeel and Bushi Wang and Vikram K. Chand and Glenwood D Goss},
  journal={The Lancet. Oncology},
  year={2015},
  volume={16 8},
  pages={897-907}
}
BACKGROUND There is a major unmet need for effective treatments in patients with squamous cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family blocker) with erlotinib (a reversible EGFR tyrosine kinase inhibitor), as second-line treatment for patients with advanced squamous cell carcinoma of the lung. METHODS We did this open-label, phase 3 randomised controlled trial at 183 cancer centres in 23 countries worldwide. We enrolled adults with stage IIIB or IV… CONTINUE READING
Highly Influential
This paper has highly influenced 11 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 85 extracted citations

Afatinib in advanced NSCLC: a profile of its use

Drugs & therapy perspectives : for rational drug selection and use • 2018
View 9 Excerpts
Highly Influenced

Role of afatinib in the treatment of advanced lung squamous cell carcinoma

Clinical pharmacology : advances and applications • 2017
View 5 Excerpts
Highly Influenced

Afatinib: A Review in Advanced Non-Small Cell Lung Cancer

Targeted Oncology • 2016
View 10 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…